We are very proud that we could partner in this successful trajectory from spin-out to a leading European diagnostics company, now to be continued on a worldwide scale.

Christophe Van Vaeck - Principal in Gimv's Health & Care tam


Multiplicom was founded in 2011 as a spin-off of the University of Antwerp and of the research institute VIB. It is specialized in the development, manufacturing and commercialization of molecular diagnostic solutions that enable clinical laboratories to identify the DNA variants associated with a genetic disease or predisposition, the results of which may be used to improve cancer therapy selection or identify congenital defects early in pregnancy.

Icon entry


Icon exit


Icon location


When ambition meets ambition

When we entered in a partnership with Multiplicom in 2011, the company already offered several diagnostic assays, including assays for breast cancer and cystic fibrosis. The company’s initial focus was on direct sales in Western Europe.

Multiplicom had also the ambition to develop a broad range of CE-labeled diagnostic assays that help patients and doctors to better understand the genetic basis of certain diseases and predispositions, such that personalized medicine can become a reality.

Together, we build a leading company

In 2011 Gimv, Gimv managed Biotechfonds Vlaanderen, VIB and University of Antwerp (UA) together invested EUR 2.0 million in a Series-A funding round of Multiplicom, at the time, a Belgian start-up focused on molecular diagnostics.

Both our continued financial support and deep involvement enabled the company to develop its innovative diagnostic tests, in getting CE-marking for its test kits, and in building a sales network in the EU.

In 2012, Multiplicom was the first diagnostic company in Europe to be awarded CE certification for its test to detect genetic defects that might indicate an increased risk of breast or ovarian cancer.

In 2016, Multiplicom got acquired by Agilent Technologies, a global leader in life sciences, diagnostics and applied chemical markets, that opened the opportunity for Multiplicom to offer its products and technology to a global customer base. We are very proud that we could partner in this successful trajectory from spin-out to a leading European diagnostics company with state-of-the-art genetic testing technology and products.


Molecular diagnostics
Exit date